Chester County News and Community Website
NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) reported third-quarter financial results and detailed a series of strategic and regulatory milestones that collectively secured more than $147 million …
Orchestra BioMed’s Big Cash Infusion Sets Stage for High-Stakes Cardiology Trials Read More NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) announced it will host a business update call on Wednesday, November 12, at 8:00 a.m. ET to discuss a series …
Orchestra BioMed to Deliver Major Business Update Amid Rapid Clinical Momentum Read More NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) announced a new agreement with Japan’s Terumo Corporation (TYO: 4543) that grants Terumo a right of first refusal for the …
Orchestra BioMed Secures $30 Million Terumo Deal for Coronary Device Rights Read More NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) has begun enrolling patients in the Virtue SAB in the Treatment of Coronary ISR Trial, a U.S. IDE pivotal study …
Orchestra BioMed Kicks Off Pivotal U.S. Trial of Non-Coated Sirolimus Balloon Read More NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) announced that new data supporting the potential of Atrioventricular Interval Modulation (AVIM) Therapy in managing hypertensive heart disease, which was …
Orchestra BioMed to Highlight AVIM Therapy’s Potential to Transform Hypertension Care Read More NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) released new data at the HRX Live 2025 Meeting in Atlanta showing that its atrioventricular interval modulation (AVIM) therapy produces …
Orchestra BioMed Reports Long-Term Data Supporting AVIM Therapy for Hypertension Read More NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) announced new data published in JACC: Clinical Electrophysiology demonstrating the potential of its atrioventricular interval modulation (AVIM) therapy to reduce …
Orchestra BioMed Publishes Data Supporting Blood Pressure Therapy in Hypertensive Pacemaker Patients Read More NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) has reported new clinical evidence suggesting its atrioventricular interval modulation (AVIM) therapy may significantly improve heart function in patients with …
Orchestra BioMed Study Shows AVIM Therapy Could Transform Care for Hypertensive Heart Disease Read More NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) reported second-quarter 2025 results alongside a series of major financing and regulatory developments that position the company to advance its …
Orchestra BioMed Secures $111M to Advance Late-Stage Cardiac Therapies, Hits Multiple FDA Milestones Read More NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) announced a major expansion to the patient eligibility criteria for its ongoing BACKBEAT study, aimed at evaluating the effectiveness of its …
FDA Greenlights Broader Patient Access for AVIM Therapy Trial in Pacemaker Patients Read More